Pharmaceutical intermediates

Baricitinib Intermediates

3 pharmaceutical intermediates for Baricitinib. Indication: Juvenile Rheumatoid Arthritis; Alopecia Areata; COVID-19 Infection; Atopic Dermatitis; Rheumatoid Arthritis.

提交项目 All intermediates

About Baricitinib

Originator: Incyte Corp
Indication: Juvenile Rheumatoid Arthritis; Alopecia Areata; COVID-19 Infection; Atopic Dermatitis; Rheumatoid Arthritis
Approved Date: 10/08/2019
DS/DP: 03/10/2029

Available intermediates

3 intermediates currently listed for Baricitinib. Request specifications, documentation or a quotation for any item below.

Baricitinib intermediates
Product Name	CAS No.	Molecular Formula	Physical Properties
2-(1-(ethylsulfonyl)azetidin-3-ylidene)acetonitrile	1187595-85-2	/	/
1-(1-ethoxyethyl)-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole	1029716-44-6	/	/
4-(1H-Pyrazol-4-yl)-7-((2-(trimethylsilyl)ethoxy)methyl)-7H-pyrrolo[2,3-d]pyrimidine	941685-27-4	/	/

Other programs under B

Baloxavir Marboxil BDTX-1535 Bedaquiline Fumarate Belumosudil mesylate Belzutifan Bempedoic acid Beraprost Sodium Bictegravir

Building toward Baricitinib?

Tell us the step you need covered and the specification you are filing against. We will confirm supply, documentation and lead time.

提交项目联系团队

我们能如何帮助您？

获取最新活动与法规动态洞察

直接发送到您的邮箱

在此获取行业洞察与 Unibest 动态

联系我们 →